Track market-moving stories before they get noisy

ANDOVER, Mass., Oct. 22, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2026 after market close on Thursday, November 5, 2026.

TransMedics Group (NASDAQ:TMDX – Get Free Report) and iRhythm Technologies (NASDAQ:IRTC – Get Free Report) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Institutional and Insider Ownership 99.7% of TransMedics Group shares are held by institutional investors. 6.9% of TransMedics Group shares are held by insiders. Comparatively, 1.0% of iRhythm Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability This table compares TransMedics Group and iRhythm Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets TransMedics Group 22.69% 15.88% 5.95% iRhythm Technologies -1.69% 10.11% 1.53% Earnings and Valuation This table compares TransMedics Group and iRhythm Technologies”s top-line revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransMedics Group $605.49 million 4.04 $190.29 million $3.89 18.20 iRhythm Technologies $825.34 million 4.34 -$44.55 million ($0.43) -252.70 TransMedics Group has higher earnings, but lower revenue than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk TransMedics Group has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500. Comparatively, iRhythm Technologies has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.

Analyst Ratings This is a summary of current ratings and recommmendations for TransMedics Group and iRhythm Technologies, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransMedics Group 1 6 5 0 2.33 iRhythm Technologies 1 1 13 2 2.94 TransMedics Group currently has a consensus price target of $115.60, indicating a potential upside of 63.32%. iRhythm Technologies has a consensus price target of $177.53, indicating a potential upside of 63.38%. Given iRhythm Technologies’ stronger consensus rating and higher possible upside, analysts plainly believe iRhythm Technologies is more favorable than TransMedics Group.

Summary TransMedics Group beats iRhythm Technologies on 9 of the 15 factors compared between the two stocks.

(Get Free Report)

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

About iRhythm Technologies (Get Free Report)

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.

Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR Newswire

NEW YORK, Sept. 26, 2026

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost
or obligation. We would handle any matter on a contingent fee basis, whereby you would not
be responsible for out-of-pocket payment of our legal fees or expenses.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of TransMedics Group, Inc. (NASDAQ: TMDX) breached their fiduciary duties to shareholders.

If you currently own TransMedics stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].

Why Your Participation Matters:

Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/did-transmedics-group-inc-insiders-breach-their-fiduciary-duties-to-shareholders-302890731.html

SOURCE Halper Sadeh LLP

TransMedics Group, Inc. (NASDAQ:TMDX – Get Free Report) shares shot up 4.5% during mid-day trading on Tuesday after an insider bought additional shares in the company. The stock traded as high as $89.15 and last traded at $89.7060. 308,922 shares traded hands during trading, a decline of 70% from the average daily volume of 1,029,492 shares. The stock had previously closed at $85.86.

Specifically, Director David Weill acquired 1,336 shares of the stock in a transaction dated Friday, September 11th. The shares were acquired at an average cost of $81.63 per share, for a total transaction of $109,057.68. Following the completion of the transaction, the director directly owned 16,392 shares of the company’s stock, valued at approximately $1,338,078.96. The trade was a 8.87% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Wall Street Analyst Weigh In TMDX has been the subject of several research analyst reports. UBS Group cut their target price on TransMedics Group from $80.00 to $77.00 and set a “neutral” rating for the company in a research report on Wednesday, August 5th. Zacks Research downgraded TransMedics Group from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. Canaccord Genuity Group restated a “buy” rating and issued a $124.00 price target on shares of TransMedics Group in a research note on Tuesday, June 30th. Stifel Nicolaus increased their price objective on shares of TransMedics Group from $75.00 to $80.00 and gave the company a “hold” rating in a report on Thursday, June 18th. Finally, TD Cowen reiterated a “buy” rating and set a $120.00 price objective on shares of TransMedics Group in a research report on Tuesday, September 8th. Five analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $121.10.

Get Our Latest Research Report on TMDX TransMedics Group Trading Up 2.6% The stock has a market cap of $3.04 billion, a PE ratio of 22.65, a price-to-earnings-growth ratio of 1.18 and a beta of 1.90. The stock has a 50-day moving average price of $82.63 and a two-hundred day moving average price of $89.59. The company has a debt-to-equity ratio of 1.62, a current ratio of 6.62 and a quick ratio of 6.07.

TransMedics Group (NASDAQ:TMDX – Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The firm had revenue of $189.95 million during the quarter, compared to the consensus estimate of $184.00 million. During the same period last year, the firm posted $0.92 earnings per share. The company’s revenue for the quarter was up 20.7% compared to the same quarter last year. Sell-side analysts forecast that TransMedics Group, Inc. will post 1.46 earnings per share for the current fiscal year.

Institutional Trading of TransMedics Group A number of large investors have recently added to or reduced their stakes in TMDX. Goldman Sachs Group Inc. increased its position in TransMedics Group by 50.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock valued at $117,506,000 after acquiring an additional 322,353 shares during the last quarter. Braidwell LP raised its stake in shares of TransMedics Group by 85.1% in the second quarter. Braidwell LP now owns 609,715 shares of the company’s stock valued at $40,497,000 after acquiring an additional 280,324 shares during the period. Deutsche Bank AG bought a new stake in shares of TransMedics Group in the 2nd quarter worth about $14,415,000. Bank of New York Mellon Corp bought a new stake in shares of TransMedics Group in the 2nd quarter worth about $12,869,000. Finally, Legal & General Group Plc purchased a new position in shares of TransMedics Group during the 2nd quarter worth about $5,286,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile (Get Free Report)

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation. The company develops and commercializes organ preservation and transport technologies designed to maintain donor organs in a functioning condition outside the body, potentially supporting evaluation and extending the time available for transplantation.

Its primary product is the Organ Care System (OCS), a portable perfusion platform that circulates oxygenated, nutrient-enriched fluid through donor organs.

See Also Five stocks we like better than TransMedics Group Running on Empty: 3 Energy Plays for Europe’s Deep Freeze 3 Healthcare Stocks for 3 Stages of Life Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into TransMedics Group, Inc. (NasdaqGM: TMDX) (“TransMedics” or the “Company”).TransMedics is a medical technology company focused on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure. The Company operates the Organ Care System, or.

, /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for transplantation, today announced the appointment of Fernando Araujo as Chief Financial Officer, effective September 21, 2026. Mr. Araujo brings more than 20 years of public-company finance leadership at GE HealthCare, General Electric, and 3M to support the Company's next phase of global growth. He succeeds Gerardo Hernandez, who will transition to Commercial Strategic Advisor, LATAM to lead TransMedics' expansion into Latin America. Concurrent with today's announcement, TransMedics is reiterating its full-year revenue guidance for 2026.

Mr. Araujo is a global finance executive with more than 20 years of public-company experience across the healthcare, industrial, and energy sectors. Most recently, he served as Chief Financial Officer of GE HealthCare's Advanced Imaging Solutions segment, a $16 billion segment combining GE HealthCare's Imaging and Advanced Visualization Solutions businesses with its global Integrated Supply Chain and Global Service organizations. He previously served as GE HealthCare's Corporate Finance CFO responsible for FP&A and Finance Transformation while closely partnering with the investor relations team. In addition, Mr. Araujo served as the Senior Vice President of Finance for Enterprise Operations at 3M. Earlier in his career, during a 17-year tenure at General Electric, he held a series of senior finance and CFO roles, including CFO of Grid Solutions Latin America, FP&A Leader for GE Energy Connections, and CFO of GE's Healthcare Latin America and Healthcare U.S. & Canada businesses.

"Fernando joins TransMedics at a growth inflection point," said Waleed Hassanein, M.D., President and Chief Executive Officer. "We are focused on scaling rapidly across strategic dimensions of our business to stimulate U.S. NOP heart and lung growth, expand our product pipeline with OCS Kidney and OCS Gen-3.0, drive operating leverage, and build out our international NOP commercial and logistics footprint across Europe. Fernando's track record of scaling finance operations at complex, global healthcare businesses is well aligned with what's ahead of TransMedics, and we are confident he will help us capitalize on the significant growth opportunities ahead. I am delighted to welcome Fernando to TransMedics."

"I am excited to join TransMedics at such an important stage in the Company's growth," said Mr. Araujo. "TransMedics has differentiated technology, an industry leadership position, and multiple near-term potential growth catalysts. I look forward to partnering with the leadership team to support disciplined execution, expand operating leverage, and create lasting value for shareholders while advancing the Company's mission for transplant patients."

Dr. Hassanein concluded, "I would like to express my sincere gratitude for Gerardo's partnership and leadership over the past two years; his contributions have been central to our operational execution. Our LATAM commercial opportunity is beginning to materialize, and Gerardo is uniquely positioned to lead an early entry in the region– working directly with me and our international commercial leadership team to accelerate our expansion and capture this high-value opportunity."

2026 Financial Outlook
TransMedics is reiterating its full-year 2026 revenue guidance of $737 million to $757 million, representing approximately 22% to 25% year-over-year growth. This guidance continues to exclude any revenue contribution from the Company's recent strategic investment in PAD Aviation Service GmbH. The Company expects to revisit this outlook in conjunction with its third quarter 2026 results.

Upcoming Investor Conferences
Morgan Stanley 24th Annual Global Healthcare Conference in New York. TransMedics management will participate in a fireside chat on Monday, September 14, 2026, at 3:20 p.m. Eastern Time.

Baird 2026 Global Healthcare Conference in New York. TransMedics management will participate in a fireside chat on Tuesday, September 15, 2026, at 9:40 a.m. Eastern Time.

A live and archived webcast of both fireside chats will be available in the "Investors" section of the TransMedics website at https://investors.transmedics.com, where the Company's standard investor presentation is also available.

About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Forward-Looking Statements

This press release contains forward-looking statements with respect to, among other things, future results and events, including a leadership transition, our full-year guidance and projected estimates, potential clinical outcomes and therapies, and statements about our operations, operational execution, financial position, strategic plans and other business plans. For this purpose, all statements other than statements of historical facts are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "could," "target," "predict," "seek" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties. Our management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: the fluctuation of our financial results from quarter to quarter; our ability to attract, train and retain key personnel; our dependence on the success of the OCS; our ability to expand access to the OCS through our NOP; our ability to improve the OCS platform, including by developing the next generation of the OCS products or expanding into new indications and the development, and potential commercialization of our OCS Kidney device; the degree of success we experience in commercializing our OCS products for additional indications, including potentially OCS Kidney; the timing or results of clinical trials for the OCS, including pre- and post-approval studies, or other product candidates, including CHOPS; our ability to sustain profitability; our need to raise additional funding and our ability to obtain it on favorable terms, or at all; our ability to use net operating losses and research and development credit carryforwards; that we have identified a material weakness in our internal control over financial reporting, and that we may identify additional material weaknesses in the future; our ability to scale our manufacturing and sterilization capabilities to meet increasing demand for our products; the rate and degree of market acceptance of the OCS; our ability to educate patients, surgeons, transplant centers and private and public payors on the benefits offered by the OCS; our dependence on a limited number of customers for a significant portion of our revenue; our ability to maintain regulatory approvals or clearances for our OCS products in the United States, the European Union and other select jurisdictions worldwide; our ability to adequately respond to the Food and Drug Administration (the "FDA"), or other competent authorities, follow-up inquiries in a timely manner; the impact of healthcare policy changes, including recently enacted or potential future legislation or administrative actions affecting or reforming the U.S. healthcare system, Organ Procurement and Transplantation Network, or the FDA; the performance of our third-party suppliers and manufacturers; our use of third parties to transport donor organs and medical personnel for our NOP and our ability to maintain and grow our transplant logistics capabilities to support our NOP to reduce dependence on third party transportation, including by means of attracting, training and retaining pilots, and the acquisition, maintenance or replacement of fixed-wing aircraft for our aviation transportation services or other acquisitions, joint ventures or strategic investments; our ability to maintain Federal Aviation Administration, or other regulatory licenses or approvals for our aircraft transportation services; price increases of the components of our products and maintenance, parts and fuel for our aircraft; our manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against our information technology, or IT, infrastructure; the economic, political and other risks associated with our foreign operations; our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products or services infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the impact of a shutdown of the U.S. government; the extent and success of competing products or procedures that are or may become available; our ability to service our 1.50% convertible senior notes, due 2028; our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreements to which we will remain subject until maturity; the impact of any product recalls or improper use of our products; our international expansion plans and the costs related thereto, including the costs associated with maintaining, improving and expanding our commercial operations globally, including the NOP and the Company's investment in PAD Aviation; our estimates regarding revenue, expenses, capital expenditures and needs for additional financing; and other factors that may be described in our filings with the Securities and Exchange Commission (the "SEC"). Additional information will be made available in our annual and quarterly reports and other filings that we make with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

TransMedics routinely posts information that may be important to investors on the landing page of the Company's website and in the "Investors" section of the website at https://investors.transmedics.com/. Investors and potential investors are encouraged to consult the TransMedics website regularly for important information about TransMedics.

Investor Contact:
Brian Johnston
Hannah Jeffrey
332-895-3222
[email protected]

SOURCE TransMedics Group, Inc.

TransMedics Group Inc (TMDX) Shares Surge 3.2% -- What GF Score of 69 Tells Investors

On September 03, 2026, TransMedics Group Inc TMDX shares rose 3.2% to a current price of $86.98, which is situated within a 52-week range of $60.11 to $156.00. Despite today's positive movement, the stock has experienced a year-to-date decline of 28.5% and an annual decline of 18.7%.

GF Value™ verdict: Currently priced at $86.98, which is 44.8% below the GF Value estimate of $157.45. GF Score™: 69/100, indicating an above-average ranking among its peers. Most notable signal: Insider activity shows a net selling of $3.9M over the last 12 months, suggesting a cautious sentiment from insiders. Is TMDX Overvalued or Undervalued? The current price of TransMedics Group Inc TMDX at $86.98 is significantly undervalued when compared to the GF Value™ estimate of $157.45, reflecting a margin of safety of 44.8%. This substantial difference presents an intriguing opportunity for potential investors. The GF Value™ is GuruFocus' proprietary estimate of the intrinsic value of a stock, calculated using historical trading multiples, business growth patterns, and future performance projections.

However, while the undervaluation appears attractive, caution is warranted as the GF Valuation label indicates a "Possible Value Trap," which suggests that investors should be careful and consider the broader context before making any investment decisions. The current financial metrics and market sentiment should be thoroughly analyzed to ensure that this perceived undervaluation does not carry hidden risks.

How Does TMDX's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 22.4x 59.3x (5-Year Median) Forward P/E 38.9x TransMedics' current P/E ratio of 22.4x is significantly below its 5-year median P/E of 59.3x, indicating that the stock is trading at a historically low valuation level. This analysis aligns with the GF Value™ verdict, which suggests that TMDX is undervalued compared to its historical performance. Therefore, this P/E ratio reinforces the notion that there may be a compelling opportunity here, albeit with caution regarding the mentioned risk factors.

What Does TMDX's GF Score™ Tell Us? The GF Score™ is a comprehensive measure of a company's financial health and performance based on various metrics, including profitability, financial strength, and growth potential. TransMedics has a GF Score™ of 69/100, indicating that it holds an above-average position relative to its peers in the medical devices and instruments industry. Its strongest sub-rank is in growth with a score of 10/10, while its weakest area is in valuation with a score of 2/10.

Metric Rating GF Score™ 69/100 Financial Strength 5/10 Profitability 3/10 Growth 10/10 Valuation 2/10 Momentum 5/10 Overall, the scores suggest that while TransMedics shows strong growth potential, it struggles in profitability and valuation. This duality indicates that while growth prospects may be promising, the company may not yet be translating that potential into financial performance, hence the low valuation score.

What Are Gurus and Insiders Doing with TMDX? Currently, there are 2 gurus holding positions in TransMedics Group Inc TMDX, with 1 guru adding to their position while 5 have trimmed their holdings in recent quarters. This mixed sentiment among seasoned investors may reflect a cautious outlook on the stock's future.

Furthermore, insider activity over the past 12 months reveals that insiders purchased $1.0M worth of shares but sold $4.9M, resulting in a net selling of $3.9M. This trend of net selling by insiders could signal a lack of confidence in the company's near-term performance, which is an important factor for potential investors to consider.

What This Means for Investors In conclusion, TransMedics Group Inc TMDX appears to be undervalued based on the GF Value™ analysis, with a significant margin of safety of 44.8%. However, the overall picture is tempered by caution due to potential value trap risks, insider selling, and mixed sentiment from gurus. Investors should weigh these factors carefully before making any decisions.

To explore further insights and metrics, visit the TransMedics Group Inc TMDX stock page for a comprehensive analysis.

Frequently Asked Questions What is TMDX's GF Score™?

TMDX has a GF Score™ of 69/100, indicating that it is performing above average compared to its peers in the medical device industry.

Is TMDX overvalued or undervalued?

According to the GF Value™, TMDX is currently undervalued by 44.8%, suggesting a potential opportunity for investors.

What is TMDX's P/E ratio?

The current P/E ratio for TMDX is 22.4x, which is significantly lower than its 5-year median of 59.3x, indicating a historically low valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Disclosures I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.

A month has gone by since the last earnings report for TransMedics (TMDX - Free Report) . Shares have added about 10.2% in that time frame, outperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is TransMedics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

TransMedics Q2 Earnings Miss Estimates, Revenues Up Y/YTransMedics delivered earnings per share of 44 cents in the second quarter of 2026, down 52.2% year over year. The figure missed the Zacks Consensus Estimate by 12%.

TMDX Revenue Mix Shows Service StrengthRevenues rose 20.7% year over year to $189.9 million and surpassed the consensus estimate by 3.1%.

Net product revenues totaled $111.2 million, up 15.7% from the prior-year quarter. The improvement was led by higher organ utilization and increased OCS adoption, particularly across the liver and heart businesses.

Service revenues represented roughly 41% of total revenues and increased 28.6% to $78.8 million. Clinical service revenues rose 19.1% to around $36 million. The stronger service contribution reflected broader logistics adoption, pricing adjustments and higher aviation-fleet utilization.

Transplant Logistics’ services revenues for second-quarter 2026 were approximately $41 million, up 39% year over year. TransMedics operated 22 owned aircraft during the quarter and covered 86% of National OCS Program missions requiring air transportation, compared with 82% coverage in the first quarter of 2026. This growth resulted from the broader adoption of TransMedics’ logistics services, increased aviation-fleet utilization and improved operating efficiency.

TMDX’s Margin TrendIn the quarter under review, TransMedics’ gross profit increased 17.2% year over year to $113.2 million. The gross margin contracted 100 basis points (bps) to 60%.

Selling, general and administrative expenses rose 31.2% year over year to $57.8 million. Research, development and clinical trials expenses surged 98.5% year over year to $31.6 million. Total operating expenses of $89.5 million increased 49.1% year over year.

Adjusted operating profit totaled $25.8 million, reflecting a decline of 29.5% from the prior-year quarter. The adjusted operating margin in the second quarter contracted 960 bps to 13.6%.  

TransMedics’ Financial PositionTransMedics exited second-quarter 2026 with cash of $472.7 million compared with $461.7 million at the end of the first quarter. Total long-term debt at the end of second-quarter 2026 was $39.7 million compared with $44.5 million at the end of the first quarter.

Cumulative net cash provided by operating activities at the end of second-quarter 2026 was $41.8 million compared with $88.8 million a year ago.

TransMedics Raises Its Revenue OutlookTransMedics raised the lower end of its 2026 revenue guidance. Revenues are now expected to be between $737 million and $757 million, representing growth of approximately 22% to 25% from the 2025 level. The previous projection called for revenues of $727 million to $757 million.

The outlook excludes contributions from PAD Aviation and assumes no incremental revenues from the ENHANCE Part B and DENOVO clinical programs. Adjusted operating margin, excluding PAD Aviation, is expected to be between 12.5% and 14%, below the company’s prior expectation of approximately 16% because of accelerated OCS Kidney investments.

How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a downward trend in fresh estimates.

The consensus estimate has shifted -31.5% due to these changes.

VGM ScoresAt this time, TransMedics has a poor Growth Score of F, however its Momentum Score is doing a bit better with a D. Following the exact same course, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.

Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise TransMedics has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.

Performance of an Industry PlayerTransMedics is part of the Zacks Medical - Instruments industry. Over the past month, IQVIA Holdings (IQV - Free Report) , a stock from the same industry, has gained 11.8%. The company reported its results for the quarter ended June 2026 more than a month ago.

IQVIA reported revenues of $4.37 billion in the last reported quarter, representing a year-over-year change of +8.7%. EPS of $3.15 for the same period compares with $2.81 a year ago.

IQVIA is expected to post earnings of $3.25 per share for the current quarter, representing a year-over-year change of +8.3%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.

IQVIA has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.

NEW YORK, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX).

If you currently own shares of TransMedics Group stock, please visit the firm's website at https://rosenlegal.com/cases/transmedics-group-inc/join for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected].

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.TMDX
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

, /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Monday, September 14, 2026, at 3:20 p.m. EST and at the Baird 2026 Global Healthcare Conference in New York on Tuesday, September 15, 2026, at 9:40 a.m. EST.

Event: Morgan Stanley 24th Annual Global Healthcare Conference
Date: Monday, September 14, 2026
Time: 3:20 p.m. EST

Event: Baird 2026 Global Healthcare Conference
Date: Tuesday, September 15, 2026
Time: 9:40 a.m. EST

A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/. The Company's standard investor presentation is also available through this link.

About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact:
Brian Johnston
Hannah Jeffrey
332-895-3222
[email protected]

SOURCE TransMedics Group, Inc.

, /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into TransMedics Group, Inc. (NasdaqGM: TMDX) ("TransMedics" or the "Company").

TransMedics is a medical technology company focused on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure. The Company operates the Organ Care System, or OCS, and the National OCS Program, or NOP.

On January 10, Scorpion Capital released a report alleging that, based on a "6-month investigation with over 30 interviews, including ex-employees, surgeons, leading transplant centers, organ procurement organizations, competitors, and its largest customers," the Company had engaged in fraudulent billing, coercive business practices, and unsafe organ transplantation, as well as extortion, racketeering, and organ trafficking under the guise of a medical device company.

Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period in violation of federal securities laws, which remains ongoing.

KSF's investigation is focusing on whether TransMedics' officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws. 

If you have information that would assist KSF in its investigation, or have been a long-term holder of TransMedics shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-538-3606 or email KSF Managing Partner Lewis Kahn ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgm-tmdx/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner

[email protected]

1-833-538-3606

1100 Poydras St., Suite 960

New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

SOURCE Kahn Swick & Foti, LLC

Emerald Investment Advisers LLC bought a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 30,456 shares of the company’s stock, valued at approximately $2,023,000. Emerald Investment Advisers LLC owned approximately 0.09% of TransMedics Group at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Royal Bank of Canada lifted its stake in TransMedics Group by 47.9% during the 1st quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock valued at $1,788,000 after acquiring an additional 8,604 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of TransMedics Group by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock valued at $1,314,000 after purchasing an additional 868 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of TransMedics Group by 20.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock valued at $34,145,000 after acquiring an additional 86,721 shares during the period. Russell Investments Group Ltd. grew its position in shares of TransMedics Group by 13.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company’s stock valued at $1,059,000 after acquiring an additional 938 shares during the period. Finally, M&T Bank Corp purchased a new position in shares of TransMedics Group during the 2nd quarter valued at approximately $209,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analyst Weigh In A number of equities analysts have weighed in on the stock. Piper Sandler restated an “overweight” rating and set a $100.00 price objective (down from $120.00) on shares of TransMedics Group in a research report on Wednesday, August 5th. Weiss Ratings lowered shares of TransMedics Group from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, July 28th. Wall Street Zen lowered shares of TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Needham & Company LLC cut their target price on shares of TransMedics Group from $142.00 to $106.00 and set a “buy” rating for the company in a research note on Monday, August 3rd. Finally, Canaccord Genuity Group restated a “buy” rating and set a $124.00 price target on shares of TransMedics Group in a research report on Tuesday, June 30th. Six research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $124.18.

Read Our Latest Research Report on TMDX TransMedics Group Stock Up 4.3% Shares of TMDX opened at $94.77 on Friday. TransMedics Group, Inc. has a 52-week low of $60.10 and a 52-week high of $156.00. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. The stock has a fifty day simple moving average of $77.49 and a two-hundred day simple moving average of $95.32. The company has a market capitalization of $3.28 billion, a PE ratio of 24.36 and a beta of 1.90.

TransMedics Group (NASDAQ:TMDX – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.06). TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The firm had revenue of $189.95 million for the quarter, compared to analyst estimates of $184.00 million. During the same period in the previous year, the firm posted $0.92 EPS. The company’s revenue was up 20.7% compared to the same quarter last year. As a group, equities analysts forecast that TransMedics Group, Inc. will post 1.47 EPS for the current year.

Insider Buying and Selling In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the transaction, the director directly owned 16,642 shares of the company’s stock, valued at $1,249,148.52. The trade was a 36.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by company insiders.

TransMedics Group Company Profile (Free Report)

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

Further Reading Five stocks we like better than TransMedics Group 2 Biotech Stocks Shaping Up for Major Breakouts 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit? Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX – Free Report).

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.

New York, New York--(Newsfile Corp. - August 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX).

If you currently own shares of TransMedics Group stock, please visit the firm's website at https://rosenlegal.com/cases/transmedics-group-inc/join for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected].

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/310469

Source: The Rosen Law Firm PA

August 18, 2026 1. Alphabet's $10 Million Shortcut to Real-World AI Data

Source: Image created by Jester AI.

Alphabet (GOOG -0.61%) won a bankruptcy auction for the wreckage of collapsed budget carrier Spirit Aviation Holdings. It's paying $10 million for a trove of business data to feed into its AI models: 100 million emails, 500 million Microsoft Teams messages, 30 million lines of code, and 175,000 employee records dating back to 1986.

Real corporate data is scarce: $10 million barely registers against Alphabet's balance sheet. What it buys matters more, in this case, years of real enterprise emails, code, and internal chatter. It's the kind of labeled, real-world data that's far harder to find than public web text. Buying a bankrupt company's digital estate is now a cheap way to get it. Expect more deals like this and eventually tighter rules on them: Distressed companies are sitting on troves like Spirit's, and AI labs need the fuel. More bankruptcy-driven data buys are coming across industries, and regulators and privacy advocates will eventually push back once someone's old emails end up training a chatbot. That fight would raise the cost of these deals. It wouldn't end them: Employee and customer data is too valuable for AI labs to walk away from. 2. Tesla's Self-Driving Promise Close to Hitting the Street The Information reports Tesla (TSLA -0.87%) is telling employees to prepare for a public launch of its driverless Cybercab in Austin as soon as this month. Employees would ride first on public roads. Tesla would then fold the cars into its existing Austin robotaxi service days later. Tesla didn't deny the report. It launched a lottery for rides at an event tied to the same timeline right after the story broke.

Years of promises meet reality: Elon Musk has said Tesla would solve self-driving "this year" for several years running. Unsupervised rides in a car with no steering wheel would be the clearest proof yet that this is finally the year the promise holds. The business model shifts with it: Last week, Fool contributing analyst Lou Whiteman discussed the company with TMF co-founder and CEO Tom Gardner. They said, "The progressive commercialization of Full Self-Driving (FSD) and driverless ride-hailing networks shifts Tesla's financial model from capital-intensive manufacturing to asset-light, high-margin software licensing and platform fees." As a result, "Tesla is well-positioned to be a net beneficiary of the AI revolution rather than a victim."

3. Rising Yields and Oil Prices Hit Nasdaq Futures

Nasdaq futures fell close to 1% in pre-market trading as U.S. Treasury yields climbed and the U.S.-Iran ceasefire expired. Tehran is threatening a more aggressive military posture, pushing Brent crude above $90 a barrel. The 30-year Treasury yield topped 5.3%, its highest level in almost two decades, and the 10-year approached 4.74%.

Rate-sensitive tech takes the hit: Higher oil raises inflation risk and the odds of tighter financial conditions, a bad combination for expensive technology stocks. Growth stocks price in profits years out, so when long-term rates rise, those future profits are worth less today. That's why the Nasdaq, not the Dow, is leading the futures decline. The AI thesis isn't broken by a rate move: Nothing here changes what AI companies are actually building or spending. Watch adoption and capital expenditure (capex) data for the real test of the thesis, not a futures dip driven by an overnight headline. A one-day move like this isn't a reason to sell AI winners.

4. Meta's Child-Safety Reckoning Continues

Meta Platforms (META -3.54%) heads to trial today in Oakland, where California and a coalition of 29 states will argue the company built Facebook and Instagram to be addictive to kids. Meta already lost a similar fight in New Mexico this month. It was ordered to pay $942 million combined between a jury verdict and a child-safety abatement fund. States now want as much as $200 billion from Meta nationwide; Meta's own lawyers have floated a worst-case number near $1.4 trillion.

The math behind the risk: Meta pulls 98% of its revenue from advertising, the same engine funding Mark Zuckerberg's roughly $145 billion AI infrastructure spend this year. States want it to strip out infinite scroll, autoplay, and engagement-optimized algorithms nationwide, changes that would hit the recommendation engine behind that same ad targeting. Watch the verdict, not the opening bell: The trial's start date changes nothing for a long-term holder. What would change it is a ruling that forces Meta to gut the algorithms driving engagement, since those algorithms are also what make its ad targeting valuable. Until there's a verdict with real remedies attached, this is a legal cloud on the stock, not a reason to sell it. 5. TransMedics Delivers Few stocks have tested our conviction like TransMedics (TMDX -0.26%). In the last two years, a short report and concerns about growth have halved the stock from the $160s to the high $80s. Yet Team Hidden Gems and Team Rule Breakers have recommended the founder-led company more than 30 times since 2019. Today, it trades near $88 -- up nearly 280% since our first recommendation.

TransMedics cracked a decades-old medical problem. Its Organ Care System keeps donor hearts, livers, and lungs warm and functioning outside the body, so more survive the trip to patients.

A moat with wings: TransMedics flies donor organs on its own fleet of 22 aircraft and now handles 86% of missions in-house. That vertical integration widens with every new route added. Spending to win: Revenue hit a record $190 million last quarter, up 21%. Management raised the low end of its full-year guidance. TransMedics is pouring that money into aircraft, a European hub, and a kidney program. It's pinching margins now to ultimately widen the moat. Team Hidden Gems has a 5-year price prediction of $268.88.

Team Rule Breakers has a midpoint 5-year price prediction of $141.50.

HG targets over 20% per year. RB targets 10% per year. And Fidelity owns a whopping 15% of the company.

6. Your Take If your portfolio comprised just Home Depot (HD -0.29%), Target (TGT -2.25%), and TJX Companies(NYSE:TJX) and you bought each of them at the start of the year with the same amount of money and had to buy more shares in one, completely close your position in another, and hold the final stock, what are you choosing to do and why?

Debate with friends and family, or become a member to hear what your fellow Fools are saying!

The Motley Fool has positions in and recommends Alphabet, Home Depot, Meta Platforms, Target, Tesla, and TransMedics Group. The Motley Fool has a disclosure policy.

NEW YORK, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX).

If you currently own shares of TransMedics Group stock, please visit the firm’s website at https://rosenlegal.com/cases/transmedics-group-inc/join for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected].

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:        

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into TransMedics Group, Inc. (NasdaqGM: TMDX) (“TransMedics” or the “Company”). TransMedics is a medical technology company focused on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure. The Company operates the Organ Care System,.

NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). If you currently own shares of TransMedics Group stock, please visit the firm's website at https://rosenlegal.com/cases/transmedics-group-inc/join for more information.

NEW YORK, Aug. 08, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX).

If you currently own shares of TransMedics Group stock, please visit the firm’s website at https://rosenlegal.com/cases/transmedics-group-inc/join for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected].

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:        

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Posted by Defense World Staff on Aug 6th, 2026

TransMedics Group, Inc. (NASDAQ:TMDX – Get Free Report) shares gapped down prior to trading on Wednesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $80.75, but opened at $72.34. TransMedics Group shares last traded at $74.30, with a volume of 847,115 shares traded.

The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.06). The firm had revenue of $189.95 million for the quarter, compared to analysts’ expectations of $184.00 million. TransMedics Group had a net margin of 22.69% and a return on equity of 16.58%. The firm’s revenue for the quarter was up 20.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.92 EPS.

More TransMedics Group News Here are the key news stories impacting TransMedics Group this week:

Positive Sentiment: Second-quarter revenue rose 20.7% year over year to approximately $190 million, exceeding analyst expectations. TransMedics also raised its fiscal 2026 revenue outlook to $737 million-$757 million, above the roughly $733.6 million consensus estimate. TransMedics Reports Second Quarter 2026 Financial Results Positive Sentiment: Piper Sandler reaffirmed its bullish view, maintaining an overweight rating and a $100 price target, implying substantial potential upside from recent levels. Piper Sandler Reaffirms TransMedics Rating Neutral Sentiment: Analyst sentiment remains mixed. UBS moved to a neutral rating and lowered its target to $77 from $80, while Piper Sandler retained a Buy rating despite reducing its target to $100 from $120. Analyst Ratings for TransMedics Negative Sentiment: Adjusted earnings were $0.44 per share, below the $0.50 consensus estimate and down from $0.92 a year earlier. Operating profit fell 35.1% and net income declined 57.9%, indicating that growth is not currently translating into comparable profit growth. TransMedics Earnings Miss Estimates Negative Sentiment: Investors are also concerned about contracting margins, sharply higher operating expenses, weaker operating cash flow, and rising liabilities. These factors overshadowed the revenue beat and raised questions about near-term execution. TransMedics Stock Dips After Earnings Negative Sentiment: Rosen Law Firm announced an investigation into potential fiduciary-duty breaches by TransMedics’ directors and officers, adding legal and reputational uncertainty. Reported insider activity also shows eight sales and no purchases over the past six months. Rosen Law Firm Investigation of TransMedics Analyst Ratings Changes Several analysts have commented on TMDX shares. Needham & Company LLC decreased their price objective on shares of TransMedics Group from $142.00 to $106.00 and set a “buy” rating for the company in a research note on Monday. Wall Street Zen downgraded shares of TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Oppenheimer downgraded TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 6th. TD Cowen reissued a “buy” rating and issued a $120.00 price objective on shares of TransMedics Group in a report on Wednesday, July 1st. Finally, Zacks Research lowered TransMedics Group from a “hold” rating to a “strong sell” rating in a report on Monday, July 6th. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, TransMedics Group currently has a consensus rating of “Hold” and an average price target of $124.18.

Read Our Latest Research Report on TransMedics Group

Insiders Place Their Bets In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the transaction, the director owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. The trade was a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group Several institutional investors and hedge funds have recently modified their holdings of TMDX. Hussman Strategic Advisors Inc. purchased a new position in shares of TransMedics Group in the fourth quarter valued at approximately $1,788,000. Baillie Gifford & Co. lifted its holdings in TransMedics Group by 21.4% in the 4th quarter. Baillie Gifford & Co. now owns 316,473 shares of the company’s stock valued at $38,499,000 after purchasing an additional 55,754 shares in the last quarter. Candriam S.C.A. boosted its stake in TransMedics Group by 45.4% during the 1st quarter. Candriam S.C.A. now owns 158,766 shares of the company’s stock worth $15,783,000 after purchasing an additional 49,580 shares during the last quarter. M&T Bank Corp grew its holdings in shares of TransMedics Group by 749.2% during the fourth quarter. M&T Bank Corp now owns 18,572 shares of the company’s stock worth $2,259,000 after buying an additional 16,385 shares in the last quarter. Finally, Regency Capital Management Inc. DE acquired a new stake in shares of TransMedics Group in the first quarter valued at about $2,172,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Trading Down 5.3% The stock has a market capitalization of $2.64 billion, a PE ratio of 19.66 and a beta of 1.90. The company’s 50 day moving average price is $73.14 and its two-hundred day moving average price is $99.24. The company has a debt-to-equity ratio of 1.70, a current ratio of 6.74 and a quick ratio of 6.19.

About TransMedics Group (Get Free Report)

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

Further Reading Five stocks we like better than TransMedics Group SpaceX: Love the Company, But the Stock Is a Harder Call Ulta’s Growth Is Real, But So Are the Risks BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBone Biologics (BBLG) to Announce Earnings on Thursday

NEXT HEADLINE »Cardiol Therapeutics (CRDL) Expected to Post Earnings on Thursday

Shares of leading, next-gen organ transplant systems specialist TransMedics (TMDX -6.85%) are down 8% as of 1 p.m. ET Wednesday after the company reported underwhelming second-quarter earnings. Sales growth of 21% beat analysts' hopes, but adjusted net income was more than halved, falling short of expectations. While TransMedics' adjusted net income dropped from $35 million last year to $16 million in Q2 this year, it is worth noting that $19 million of this change comes from spending on a next-gen Kidney organ care system (OCS), two new clinical programs, and a manufacturing plant in Italy. Simply put, the company remains a growth stock happy to reinvest in its operations, so its earnings may be lumpy like this at times -- nothing to panic over.

Today's Change

(

-6.85

%) $

-5.53

Current Price

$

75.22

All in all, it was a solid Q2 for TransMedics as:

product revenue rose 16% service sales increased 29% TransMedics' owned aircraft covered 86% of National OCS Program (NOP) donations sales outside the U.S. jumped 26% liver revenue soared 27% (TMDX's largest category) management boosted 2026 sales guidance from 20% to 25% growth to between 22% and 25%

Image source: The Motley Fool.

While TransMedics' growth rates may not be as lofty as they once were, the stock's 41% decline over the last year has it squarely on my radar for additions again, especially trading around 34 times next year's projected earnings. Furthermore, although sales growth may have slowed temporarily, TransMedics has several growth opportunities directly ahead.

First, the company's Enhance and Denovo clinical trials could restart growth within its heart and lung donation segments. These currently account for less than one-fourth of TransMedics' sales. Second, the company continues to work on a new kidney OCS, which could grant it access to "the single largest addressable segment available to us in organ transplantation in the U.S. and around the world," according to President and CEO Waleed Hassanein. This is still a couple of years out, but could be a big development for the stock.

This growth potential -- paired with ongoing expansion plans in Europe -- keeps TransMedics a buy for me after Q2's earnings.

Josh Kohn-Lindquist has positions in TransMedics Group. The Motley Fool has positions in and recommends TransMedics Group. The Motley Fool has a disclosure policy.

Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayTransMedics Group NASDAQ: TMDX reported record second-quarter revenue as growth in liver procedures, clinical services and transplant logistics offset increased spending on product development, international expansion and infrastructure.

Total revenue for the quarter ended June 30 rose 21% year over year and 9% sequentially to approximately $190 million. Transplant product revenue increased 16% to $111 million, while service revenue climbed 29% to $79 million. Service revenue accounted for 41% of total revenue during the quarter.

Get TransMedics Group alerts:

3 Medical Technology Stocks Outperforming in 2025President and Chief Executive Officer Waleed Hassanein said the quarter was the company’s strongest to date in both revenue and case volume. Liver revenue growth led the performance, increasing approximately 28% from a year earlier and 7% sequentially. Heart revenue rose approximately 6% year over year and 23% from the first quarter.

Logistics Growth Supports Service Revenue TransMedics’ logistics business generated approximately $41 million in revenue, up 39% from the prior-year quarter and 30% sequentially. The company said its TransMedics Logistics network covered about 86% of National OCS Program missions requiring air transport, compared with 82% in the first quarter.

3 High-Growth Stocks Traders Love and Investors Should WatchHassanein attributed the service-revenue performance to logistics market-share gains, operational efficiencies, pricing adjustments intended to offset higher costs and new transplant-center customers. He said the company did not see an increase in dry-run rates during either the second or third quarter.

Chief Financial Officer Gerardo Hernandez said total gross margin was 59.6%, improving about 140 basis points sequentially but declining roughly 180 basis points year over year. Service margin rose to 35% from approximately 27% in the first quarter, supported by higher fleet utilization and operating efficiencies. Product gross margin was 77%, broadly stable sequentially.

The year-over-year gross-margin decline reflected a greater mix of service revenue as well as temporary product cost pressures, including inventory provisioning and trial-related solution costs, according to Hernandez. The company expects service margin to normalize somewhat in the second half while remaining above historical levels.

Investment Priorities Include Kidney, Clinical Programs and Europe Management emphasized that TransMedics is prioritizing long-term revenue growth over near-term operating leverage. The company is funding four principal initiatives over the next 18 to 24 months: expanding heart and lung adoption, developing its OCS Kidney platform, building a European logistics network and advancing its next-generation OCS Gen 3.0 platform.

Hassanein said the company expects its platform could support approximately 30,000 transplants globally by 2032 and generate more than $2 billion in annual revenue. The target includes current heart, lung and liver operations, new clinical programs, kidney development and international expansion.

For heart and lung, TransMedics is pursuing ENHANCE Heart Part B and the DENOVO Lung program. The company said the programs could provide access to an estimated 2,000 to 5,000 incremental U.S. heart and lung cases annually. The FDA is reviewing an investigational device exemption supplement incorporating the company’s Controlled Hypothermic Organ Preservation System, or CHOPS, into the ENHANCE trial. Management expects approval by late in the third quarter or early in the fourth quarter, followed by a lung IDE submission.

Hassanein said ENHANCE Heart Part A is expected to be completed before year-end. Part B and DENOVO Lung have each completed only a handful of cases so far, he said, and did not make a meaningful contribution to second-quarter results. Management expects the clinical programs to be completed within 12 to 18 months after enrollment accelerates.

The company also said it has started pre-IDE discussions with the FDA for OCS Kidney, including its first pre-submission meeting. TransMedics is targeting first clinical experience for the kidney program later in 2027.

“This is the single largest addressable segment available to us in organ transplantation in the U.S. and around the world,” Hassanein said, citing more than 21,000 deceased-donor kidney transplants performed annually in the U.S.

European Platform Begins With PAD Aviation Investment On July 1, TransMedics closed its strategic investment in PAD Aviation, a Germany-based aviation operator. The company said PAD provides aviation licensing, pilots and fleet access needed to establish TransMedics Aviation Europe and compete for transplant-logistics tenders across the region.

Hassanein clarified that the investment does not mean TransMedics has begun commercial operations in Germany. Instead, he said PAD’s location in Paderborn provides access to potential European donor sites within roughly two hours of flight time. Germany is not viewed as a near-term growth catalyst because of reimbursement limitations and the absence of donation after circulatory death procedures, he added.

TransMedics said it has secured a machine-perfusion and services budget in Italy that is expected to take effect later this year or in early 2027 following administrative steps. The company is also pursuing regional transplant-logistics tenders in Italy and is evaluating opportunities in other European countries with existing reimbursement budgets.

PAD will be consolidated beginning in the third quarter. Hernandez said the business will initially dilute gross margin and operating margin, and the company is not yet providing standalone financial guidance for PAD. Management expects to provide additional detail after further integration work in the third quarter.

Guidance Raises Revenue Floor, Lowers Margin Outlook TransMedics raised the low end of its full-year 2026 revenue outlook, excluding PAD Aviation, to a range of $737 million to $757 million. The guidance represents growth of approximately 22% to 25% over 2025 and assumes no revenue contribution from PAD and no meaningful incremental revenue from ENHANCE Part B or DENOVO.

The company expects second-half gross margin, excluding PAD, of approximately 59%. It now forecasts a full-year adjusted operating margin of approximately 12.5% to 14%, excluding PAD, below its earlier expectation of about 16%.

Hernandez said the reduced margin outlook primarily reflects accelerated investment in OCS Kidney rather than a broad expansion of overhead. Adjusted operating expenses were $87 million in the quarter, up 46% year over year. About $14 million of that increase was tied to OCS Kidney, next-generation OCS, and the ENHANCE and DENOVO programs, while approximately $5 million was related to the company’s new headquarters and disposable manufacturing facility in Mirandola, Italy.

Adjusted income from operations was $25.8 million, representing a 13.6% operating margin. Adjusted net income was $16.2 million, or $0.44 per diluted share. TransMedics ended the quarter with approximately $473 million in cash and cash equivalents.

Management said it remains cautious on the seasonally softer third quarter despite a strong July, which Hassanein described as the company’s highest aviation month. The company said it will provide a fuller outlook for 2027 when it reports fourth-quarter results.

About TransMedics Group (NASDAQ:TMDX)TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in TransMedics Group Right Now?Before you consider TransMedics Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.

While TransMedics Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

For the quarter ended June 2026, TransMedics (TMDX - Free Report) reported revenue of $189.95 million, up 20.7% over the same period last year. EPS came in at $0.44, compared to $0.92 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $184.17 million, representing a surprise of +3.14%. The company delivered an EPS surprise of -12%, with the consensus EPS estimate being $0.50.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how TransMedics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

OCS transplant revenue- United States- Total: $183.62 million versus $177.1 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +20.7% change.OCS transplant revenue- United States- Lung total revenue: $2.25 million versus the three-analyst average estimate of $2.83 million.OCS transplant revenue- United States- Heart total revenue: $33.38 million compared to the $30.21 million average estimate based on three analysts.OCS transplant revenue- United States- Liver total revenue: $147.99 million versus the three-analyst average estimate of $144.05 million.OCS transplant revenue- All other countries- Total: $5.24 million compared to the $5.15 million average estimate based on three analysts. The reported number represents a change of +26% year over year.OCS transplant revenue- All other countries- Lung total revenue: $0.41 million compared to the $0.48 million average estimate based on three analysts.OCS transplant revenue- All other countries- Heart total revenue: $4.59 million compared to the $4.5 million average estimate based on three analysts.OCS transplant revenue- All other countries- Liver total revenue: $0.25 million compared to the $0.26 million average estimate based on two analysts.Revenue- Service: $78.79 million versus the two-analyst average estimate of $69.04 million. The reported number represents a year-over-year change of +28.6%.Revenue- Net Product: $111.16 million versus the two-analyst average estimate of $113.35 million. The reported number represents a year-over-year change of +15.7%.View all Key Company Metrics for TransMedics here>>>

Shares of TransMedics have returned +14.5% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.

, /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2026.

Recent Highlights

Total revenue of $189.9 million in the second quarter of 2026, a 21% increase compared to the second quarter of 2025 Product revenue of $111.2 million, up 16% and Service revenue of $78.8 million, up 29% Net income of $14.7 million or $0.41 per fully diluted share in the second quarter of 2026 Adjusted net income of $16.2 million or $0.44 per fully diluted share in the second quarter of 2026 Raised low end of full-year 2026 revenue guidance, excluding PAD Aviation, to a range of $737 million to $757 million On July 1, 2026, completed its strategic investment in PAD Aviation, a premier Germany-based private aviation operator, as the first step to establishing a dedicated organ transplantation air logistics network across Europe, and beyond "The second quarter was a defining one for TransMedics: record revenue, accelerating service growth, and sequential gross margin expansion, all as we invested aggressively in our strategic priorities," said Waleed Hassanein, MD, President and Chief Executive Officer. "Let me be direct about how we see our business: we are building TransMedics to remain a growth company in the near, mid, and long terms. We are deploying capital behind four distinct growth opportunities that we believe will drive substantial revenue growth with a compelling operating profile at scale. Our confidence is derived from our team's proven track record of converting investment into results, quarter after quarter. It is also grounded in the unparalleled nature of our offering: the life-saving impact of our OCS technology, the reach of our NOP platform, and the extraordinary people who deliver it. Our mission has not changed — expand access and improve outcomes for every patient waiting for an organ transplant. We are more inspired by what lies ahead than at any point in our history."

A summary of second quarter financial results is as follows (dollars in thousands except per share):

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

% Change

2026

2025

% Change

Revenue

$

189,948

$

157,370

21

%

$

363,881

$

300,907

21

%

Income from operations

$

23,736

$

36,567

-35

%

$

37,033

$

64,010

-42

%

Operating margin %

12.5

%

23.2

%

-1074bps

10.2

%

21.3

%

-1110bps

Adjusted income from operations(1)

$

25,791

$

36,567

(2)

-29

%

$

43,900

$

66,368

-34

%

Adjusted operating margin %(1)

13.6

%

23.2

%

(2)

-960bps

12.1

%

22.1

%

-1000bps

Diluted net income per share

$

0.41

$

0.92

-55

%

$

0.61

$

1.62

-62

%

Adjusted diluted net income per share(1)

$

0.44

$

0.92

(2)

-52

%

$

0.75

$

1.67

-55

%

(1)

Adjusted income from operations, adjusted operating margin and adjusted diluted net income per share represent non-GAAP financial measures. For a reconciliation of GAAP to Non-GAAP items, please see the tables attached to this press release.

(2)

There were no adjustments excluded from GAAP income from operations or diluted net income per share for the three months ended June 30, 2025; therefore, non-GAAP adjusted income from operations and adjusted diluted net income per share were equal to GAAP income from operations and diluted net income per share, respectively.

Second Quarter 2026 Financial Results
Total revenue for the second quarter of 2026 was $189.9 million, a 21% increase compared to $157.4 million in the second quarter of 2025. The increase was due primarily to the increase in utilization of the Organ Care System ("OCS"), primarily in Liver and Heart through the National OCS Program ("NOP") as well as additional revenue generated by TransMedics logistics services.

Gross margin was 60%, compared with 61% in the prior-year period. The year-over-year decrease primarily reflected a higher mix of service revenue, and temporary product-cost factors, including inventory provisioning and trial-related solution cost, partly offset by improved logistics efficiency.

Operating expenses for the second quarter of 2026 were $89.5 million compared to $60.0 million in the second quarter of 2025. The increase in operating expenses was driven primarily by planned investment in OCS Kidney, Gen 3.0 and clinical programs, together with selected infrastructure investments required to support the company's growth. Second quarter operating expenses in 2026 included $8.2 million of stock compensation expense compared to $9.0 million of stock compensation expense in the second quarter of 2025.

Income from operations in the second quarter of 2026 was $23.7 million, compared to operating income of $36.6 million in the second quarter of 2025. Adjusted income from operations in the second quarter of 2026 was $25.8 million compared to adjusted income from operations of $36.6 million in the second quarter of 2025.

Net income in the second quarter of 2026 was $14.7 million, or $0.41 per diluted share, compared to net income of $34.9 million, or $0.92 per diluted share, in the second quarter of 2025. Adjusted net income in the second quarter of 2026 was $16.2 million, or $0.44 per diluted share compared to adjusted net income of $34.9 million, or $0.92 per diluted share, in the second quarter of 2025.

Cash was $472.7 million as of June 30, 2026.

2026 Financial Outlook
TransMedics is raising the low end of its full-year 2026 revenue guidance to a range of $737 million to $757 million. This guidance excludes any revenue attributable to the recent strategic investment in PAD Aviation service GmbH, assumes no incremental revenue from the ENHANCE Part B and DENOVO clinical trials, and represents approximately 22% to 25% growth compared to the company's prior year revenue. TransMedics' full year 2026 revenue guidance as reported on May 5, 2026 was previously in the range of $727 million to $757 million.

Webcast and Conference Call Details
The TransMedics management team will host a conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT on Tuesday, August 4, 2026. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 6054544. A live and archived webcast of the event and the company's slide presentation with information on second quarter 2026 financial results will be available on the "Investors" section of the TransMedics website at www.transmedics.com.

About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. TransMedics routinely posts information that may be important to investors on the landing page of the Company's website and in the "Investors" section of the website at https://investors.transmedics.com/. Investors and potential investors are encouraged to consult the TransMedics website regularly for important information about TransMedics.

Forward-Looking Statements
This press release contains forward-looking statements with respect to, among other things, future results and events, including financial guidance and projected estimates, potential clinical outcomes and therapies, and statements about our operations, operational execution, financial position, strategic plans and other business plans. For this purpose, all statements other than statements of historical facts are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "could," "target," "predict," "seek" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties. Our management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: the fluctuation of our financial results from quarter to quarter; our ability to attract, train and retain key personnel; our dependence on the success of the OCS; our ability to expand access to the OCS through our NOP; our ability to improve the OCS platform, including by developing the next generation of the OCS products or expanding into new indications and the development, and potential commercialization of our OCS Kidney device; the degree of success we experience in commercializing our OCS products for additional indications, including potentially OCS Kidney; the timing or results of clinical trials for the OCS, including pre- and post-approval studies, or other product candidates, including CHOPS; our ability to sustain profitability; our need to raise additional funding and our ability to obtain it on favorable terms, or at all; our ability to use net operating losses and research and development credit carryforwards; that we have identified a material weakness in our internal control over financial reporting, and that we may identify additional material weaknesses in the future; our ability to scale our manufacturing and sterilization capabilities to meet increasing demand for our products; the rate and degree of market acceptance of the OCS; our ability to educate patients, surgeons, transplant centers and private and public payors on the benefits offered by the OCS; our dependence on a limited number of customers for a significant portion of our revenue; our ability to maintain regulatory approvals or clearances for our OCS products in the United States, the European Union and other select jurisdictions worldwide; our ability to adequately respond to the Food and Drug Administration (the "FDA") or other competent authorities, follow-up inquiries in a timely manner; the impact of healthcare policy changes, including recently enacted or potential future legislation or administrative actions affecting or reforming the U.S. healthcare system, Organ Procurement and Transplantation Network, or the FDA; the performance of our third-party suppliers and manufacturers; our use of third parties to transport donor organs and medical personnel for our NOP and our ability to maintain and grow our transplant logistics capabilities to support our NOP to reduce dependence on third party transportation, including by means of attracting, training and retaining pilots, and the acquisition, maintenance or replacement of fixed-wing aircraft for our aviation transportation services or other acquisitions, joint ventures or strategic investments; our ability to maintain Federal Aviation Administration, or other regulatory licenses or approvals for our aircraft transportation services; price increases of the components of our products and maintenance, parts and fuel for our aircraft; our manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against our information technology, or IT, infrastructure; the economic, political and other risks associated with our foreign operations; our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products or services infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the impact of a shutdown of the U.S. government; the extent and success of competing products or procedures that are or may become available; our ability to service our 1.50% convertible senior notes, due 2028; our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreements to which we will remain subject until maturity; the impact of any product recalls or improper use of our products; our international expansion plans and the costs related thereto, including the costs associated with maintaining, improving and expanding our commercial operations globally, including the NOP and the Company's investment in PAD Aviation; our estimates regarding revenue, expenses, capital expenditures and needs for additional financing; and other factors that may be described in our filings with the Securities and Exchange Commission (the "SEC"). Additional information will be made available in our annual and quarterly reports and other filings that we make with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

Use of Non-GAAP Financial Measures
To supplement our consolidated financial statements, which are prepared and presented in accordance with generally accepted accounting principles in the United States ("GAAP"), we disclose certain non-GAAP financial measures, including adjusted income from operations, adjusted operating margin, adjusted net income, and adjusted diluted net income per common share. These non-GAAP financial measures are not calculated in accordance with GAAP, are not a substitute for, and should be considered supplemental to, GAAP financial measures. Our definitions of these non-GAAP measures may differ from similarly titled measures used by other companies, which may limit their usefulness for comparative purposes.

We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe the presentation of these measures is useful to both management and investors as they provide meaningful supplemental information with respect to our core operational performance and allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making.

To calculate adjusted income from operations, adjusted operating margin, adjusted net income and adjusted diluted net income per common share, we exclude certain charges (credits) from GAAP income from operations and GAAP net income, such as transaction-related costs, incremental amortization of intangible assets, ERP implementation costs, headquarters relocation costs and legal matters. Amounts are presented after-tax using the company's statutory tax rate unless the amount is a significant unusual or infrequently occurring item in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate."

In reliance upon the unreasonable efforts exemption provided under Item 10(e)(1)(i)(B) of Regulation S-K, the Company is not able to provide a reconciliation of its non-GAAP financial guidance that excludes the impact of PAD aviation to the corresponding GAAP measures without unreasonable effort because of the inherent difficulty in forecasting and quantifying certain amounts necessary for such a reconciliation. Because this information is uncertain, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.

Investor Contact:
Brian Johnston
332-895-3222
[email protected]

TransMedics Group, Inc.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
(unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Revenue:

Net product revenue

$

111,158

$

96,100

$

219,130

$

184,334

Service revenue

78,790

61,270

144,751

116,573

Total revenue

189,948

157,370

363,881

300,907

Cost of revenue:

Cost of net product revenue

25,566

19,421

49,874

35,733

Cost of service revenue

51,184

41,360

99,648

80,357

Total cost of revenue

76,750

60,781

149,522

116,090

Gross profit

113,198

96,589

214,359

184,817

Gross margin

60

%

61

%

59

%

61

%

Operating expenses:

Research, development and clinical trials

31,632

15,934

56,511

33,094

Selling, general and administrative

57,830

44,088

120,815

87,713

Total operating expenses

89,462

60,022

177,326

120,807

Income from operations

23,736

36,567

37,033

64,010

Other income (expense):

Interest expense

(7,225)

(3,476)

(14,395)

(6,937)

Interest income and other income (expense), net

2,894

3,091

5,252

5,785

Total other expense, net

(4,331)

(385)

(9,143)

(1,152)

Income before income taxes

19,405

36,182

27,890

62,858

Provision for income taxes

(4,723)

(1,275)

(5,893)

(2,269)

Net income

$

14,682

$

34,907

$

21,997

$

60,589

Net income per share:

Basic

$

0.42

$

1.03

$

0.64

$

1.79

Diluted

$

0.41

$

0.92

$

0.61

$

1.62

Weighted average common shares outstanding:

Basic

34,579,980

33,912,669

34,482,634

33,817,664

Diluted

40,709,227

40,558,953

36,003,677

40,238,501

TransMedics Group, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)

June 30,

December 31,

2026

2025

Assets

Current assets:

Cash

$

472,675

$

488,366

Accounts receivable

104,138

84,282

Inventory

54,137

48,881

Prepaid expenses and other current assets

20,174

16,254

           Total current assets

651,124

637,783

Property, plant and equipment, net

365,302

327,656

Finance lease right-of-use assets, net

332,472

—

Operating lease right-of-use assets, net

4,646

5,155

Deferred tax assets

78,677

83,543

Restricted cash

18,438

500

Goodwill

11,549

11,549

Acquired intangible assets, net

—

1,948

Other non-current assets

2,188

239

           Total assets

$

1,464,396

$

1,068,373

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable

$

12,909

$

10,350

Accrued expenses and other current liabilities

58,598

62,740

Current portion of long-term debt

20,000

10,000

Deferred revenue

3,130

2,905

Operating lease liabilities

3,646

3,310

Total current liabilities

98,283

89,305

Convertible senior notes, net

454,260

452,804

Long-term debt, net

39,743

49,587

Finance lease liability

347,660

—

Operating lease liabilities, net of current portion

2,411

3,577

Other long-term liabilities

3,986

—

    Total liabilities

946,343

595,273

    Total stockholders' equity

518,053

473,100

    Total liabilities and stockholders' equity

$

1,464,396

$

1,068,373

TransMedics Group, Inc.

NON-GAAP INCOME FROM OPERATIONS, NET INCOME AND DILUTED NET INCOME PER SHARE RECONCILIATIONS

(dollars in thousands, except per share)

(unaudited)

Three Months Ended June 30, 2026

Income from
Operations

Operating
Margin %

Net Income

Diluted Net
Income per
Common Share

Reported

$

23,736

12.5

%

$

14,682

$

0.41

Non-GAAP adjustments:

Transaction-related costs(1)

1,745

0.9

%

1,304

0.03

Headquarters relocation costs(2)

65

0.1

%

49

—

ERP implementation costs(3)

245

0.1

%

183

—

Adjusted

$

25,791

13.6

%

$

16,218

$

0.44

Three Months Ended June 30, 2025

Income from
Operations

Operating
Margin %

Net Income

Diluted Net
Income per
Common Share

Reported

$

36,567

23.2

%

$

34,907

$

0.92

Non-GAAP adjustments:

—

0.0

%

—

—

Adjusted

$

36,567

23.2

%

$

34,907

$

0.92

Six Months Ended June 30, 2026

Income from
Operations

Operating
Margin %

Net Income

Diluted Net
Income per
Common Share

Reported

$

37,033

10.2

%

$

21,997

$

0.61

Non-GAAP adjustments:

Transaction-related costs(1)

4,452

1.2

%

3,327

0.09

Headquarters relocation costs(2)

272

0.1

%

204

0.01

ERP implementation costs(3)

245

0.1

%

183

—

Incremental amortization of acquired

   intangible assets(4)

1,898

0.5

%

1,418

0.04

Adjusted

$

43,900

12.1

%

$

27,129

$

0.75

Six Months Ended June 30, 2025

Income from
Operations

Operating
Margin %

Net Income

Diluted Net
Income per
Common Share

Reported

$

64,010

21.3

%

$

60,589

$

1.62

Non-GAAP adjustments:

Legal matters(5)

2,358

0.8

%

1,759

0.05

Adjusted

$

66,368

22.1

%

$

62,348

$

1.67

(1)

Transaction-related costs – These adjustments primarily reflect direct and incremental costs incurred in connection with strategic initiatives and corporate development activities, and may include due diligence, deal fees, integration and other fees and costs related to transactions. The Company excludes only costs that are directly attributable to individually identifiable transactions that have progressed beyond preliminary evaluation, including those for which formal internal approvals have been obtained or third-party advisors have been engaged. Exploratory and other ongoing corporate development and strategy-related operating expenses are not excluded. Excluded costs are associated with discrete transaction events and are not reflective of the Company's core operating performance, although similar costs may be incurred in future periods.

(2)

Headquarters relocation costs – These adjustments reflect primarily direct and incremental third-party professional fees, including valuation, accounting, and advisory services, incurred in connection with the Company's relocation of its headquarters to Somerville, Massachusetts. These costs may also include incremental depreciation of fixed assets resulting from reassessments of estimated economic lives in consideration of the relocation.  The Company excludes only costs that are directly attributable to the relocation event and does not exclude ongoing occupancy, personnel, or other recurring operating expenses associated with the new headquarters.

(3)

ERP implementation costs – These adjustments reflect direct and incremental costs incurred in connection with the design, configuration, testing, deployment, and initial implementation of a new enterprise resource planning ("ERP") system, or a significant upgrade or replacement of an existing ERP platform. Such costs may include third-party consulting, system integration, project management, data conversion, and other implementation-related professional fees. The Company excludes only costs that are directly attributable to the initial implementation or significant transformation of an ERP platform and that are non-recurring in nature. Ongoing software subscription, hosting, maintenance, support, personnel, and other recurring information technology operating expenses are not excluded.

(4)

Incremental amortization of acquired intangible assets – We record intangible assets acquired in a business combination or asset acquisition at acquisition date fair values and amortize over their estimated useful lives. These adjustments reflect non-cash charges related to incremental amortization of acquired intangible assets, resulting from periodic reassessments of estimated economic lives. These amounts are excluded as they relate to discrete, non-routine activities rather than the Company's ongoing operations and therefore are not considered indicative of normal operating costs.

(5)

Legal matters - These adjustments reflect legal fees and other directly attributable costs incurred in connection with responding to and addressing matters arising from the short-seller report issued in January 2025. Such costs may include external legal counsel, advisory services, and other incremental expenses necessary to evaluate and defend against the claims. The Company excludes only costs that are specifically associated with this discrete event and does not exclude ongoing legal expenses related to normal business operations. These costs are excluded as they are non-recurring in nature and not indicative of the Company's core operating performance, although similar costs could arise in future periods.

SOURCE TransMedics Group, Inc.

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX).If you currently own shares of TransMedics Group stock, please visit the firm's website at https://rosenlegal.com/cases/transmedics-group-inc/join for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected].

Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026. The TransMedics management team will present beginning at 2:00 p.m. ET/ 1:00 p.m. CT

A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/. The Company's standard investor presentation is also available through this link.

About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact:
Brian Johnston
Hannah Jeffrey
332-895-3222
[email protected]

SOURCE TransMedics Group, Inc.

Also from this source